Given that low XRCC1 gene expression has also been shown to enhance the cytotoxic effects of PARPi in breast cancer cell lines, we hypothesized that XRCC1 deficiency could be a promising target for treatment with PARPi in PCa and mCRPC [16], especially for AA PCa patients. The gene discussed is XRCC1; the disease is breast cancer.